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 Lung cancer causes more than 1 million deaths in every year worldwide, and is the 
leading cause of cancer-related death in the United States.  Targeting epidermal growth 
factor receptor (EGFR) in non-small cell lung cancer (NSCLC) harboring activating 
mutations in EGFR is an effective treatment but is eventually limited by drug-resistance.  
This has led to a pressing need to identify alternative treatments or additional targets for 
resistant tumors.  I found abundant activation of cyclooxygenase-2 (COX-2) signal in 
mutant EGFR NSCLC, suggesting that it might play tumorigenic roles in these tumors.  
Targeting COX-2 in mutant EGFR lung cancer cells and transgenic mouse models of 
mutant EGFR lung cancer reduced tumor cell growth, and was more effective in 
combination with EGFR inhibition.  I found that COX-2 signaling regulates interleukin-6 
(IL-6) transcription leading to signal transducer and activator of transcription 3 (STAT3) 
activation.  These findings demonstrate that COX-2 modulates the IL-6/STAT3 signaling 
axis in mutant EGFR NSCLC and targeting COX-2 in combination with EGFR inhibition 
could be an effective strategy to treat mutant EGFR NSCLC. 
Since COX-2 inhibition is a promising chemopreventive agent in other cancers; 
therefore, I next hypothesized that targeting COX-2 might be a viable strategy to prevent 
tumor formation.  Using transgenic mouse models, I found that targeting COX-2 prior to 
tumor development delayed tumor formation, which suggests that COX-2 inhibition could
be a potential strategy to delay or prevent development of mutant EGFR NSCLC. 
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In further efforts to identify other targets in mutant EGFR lung cancer, I found 
evidence of abundant activation of protein kinase C δ (PKCδ).  This kinase normally 
functions as a tumor-suppressor, but it also is considered as a tumor-promoter in some 
contexts.  I found reduced growth of mutant EGFR human lung cancer cells under PKCδ 
depletion.  I also discovered that PKCδ promotes IL-6/STAT3 signal in mutant EGFR 
NSCLC, suggesting that PKCδ is a tumor-promoter in mutant EGFR NSCLC.  
Collectively, my data indicate that PKCδ is a potential target to treat mutant EGFR 
NSCLC. 
 In this dissertation, I identified COX-2 and PKCδ as novel targets for treating 
mutant EGFR NSCLC and defined their oncogenic roles in mutant EGFR NSCLC by 
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Non-small cell lung cancer and mutant epidermal growth 
factor receptor 
Lung cancer has been the leading cause of cancer-related death in the United States 
for decades (1, 2).  Each year, this disease typically causes more than 1 million deaths 
worldwide (3).  Lung cancer is histologically divided into two subtypes, small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC).  SCLC is thought to originate in 
neuroendocrine cells and accounts for approximately 10-15% of all lung cancers (4).  
NSCLC originates in lung epithelial cells, accounts for 80% of primary lung cancers, and 
includes various histological subtypes such as adenocarcinoma, bronchioalveolar cell 
carcinoma, squamous cell carcinoma, anaplastic and large cell carcinoma (5).  Smoking is 
considered a major risk factor for NSCLC.  When compared with never-smokers, the risk 
of developing NSCLC is increased about 10- to 20-fold in smokers (6); however, globally, 
about 25% of NSCLC is found in never-smokers: 15% in men and 53% in women (3, 7).    
The major causes of NSCLC in never-smokers are likely related to environmental 
exposures such as second-hand tobacco smoke, radon and indoor coal burning (8, 9).  These 
agents are thought to cause oncogenic genetic alterations in key regulatory genes such as 
epidermal growth factor growth factor receptor (EGFR) and KRAS.  At least two lines of
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evidence suggest that EGFR plays important roles in lung tumorigenesis.  First, a number
of somatic mutations have been identified in the coding region of EGFR in tumors from 
patients diagnosed with lung cancer.  Second, retrospective analyses revealed that EGFR-
overexpression is a feature of more than 60% of NSCLC cases (10, 11). 
EGFR is a member of the ErbB family of receptor tyrosine kinases (RTKs) which 
are expressed on the cell surface and mediate signaling events elicited by extracellular 
growth factors (12, 13).  Following binding of a ligand such as EGF or transforming growth 
factor-α (TGF-α), EGFR undergoes conformational changes that facilitate the formation of 
either homo- or hetero-dimers with other members of the ErbB family.  These interactions 
result in activation of EGFR which occurs when tyrosine residues in the activation loop of 
the cytosolic domain of the receptor become phosphorylated.  Activation of EGFR initiates 
a cascade of signaling events that affect key cellular functions such as proliferation and 
survival.  The mechanisms involved in these responses involve participation of three major 
signaling pathways, including the phosphatidylinositol 3-kinase (PI3K)/Akt, Ras/mitogen-
activated protein kinase (MAPK), and signal transducer and activator of transcription 
(STAT) axes (7, 14, 15).  More than 90% of the EGFR mutations identified in NSCLC are 
accounted for by deletions in exon 19 and by a mutation in the kinase domain of the 
receptor that results in substitution of leucine 858 with arginine [L858R, (16, 17)].  These 
alterations in EGFR increase its basal and ligand-induced activity.  These conclusions were 
derived from crystallographic and biochemical studies showing that the normal auto-
inhibitory function of EGFR is disrupted in mutant forms of the receptor, leading to a 50-
fold increase in kinase activity in mutant versus wild-type EGFR (18, 19).  Hyper-
activated, mutant forms of EGFR constitutively engage downstream signaling axes such as 
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PI3K/Akt, Ras/MAPK and STAT, contributing to NSCLC.  As such, disrupting EGFR 
signaling appears to be a promising therapeutic strategy for the treatment of NSCLC 
harboring mutant forms of EGFR. 
 
Targeting EGFR and drug resistance 
NSCLC patients subjected to cytotoxic chemotherapies have moderate increases in 
survival, but this benefit is associated with significant toxicity (20).  Molecularly targeted 
therapeutics are currently viewed as more promising and safer strategies to treat NSCLC.  
Distinct subsets of cancers are characterized by specific oncogenic mutations that are 
essential for tumorigenesis and cancer cell survival, and targeting the mutant proteins 
resulting from these mutations can result in cancer cell death with limited toxicity.  Thus, 
targeting EGFR has emerged as a promising strategy to treat mutant EGFR NSCLC.  
Diverse approaches have been used to accomplish this, and various EGFR inhibitors have 
been developed and tested in human clinical trials.  These include monoclonal antibodies 
that bind to the extracellular domain of EGFR (e.g., cetuximab and matuzumab), and small 
molecules that block the tyrosine kinase activity of the receptor [e.g., gefitinib, erlotinib, 
and other tyrosine kinase inhibitors or TKIs, (21)].  Specifically, gefitinib and erlotinib 
have been reported to be highly effective in NSCLC patients with activating mutations in 
EGFR (22, 23).  Gefitinib and erlotinib act as reversible inhibitors of EGFR by 
competitively inhibiting binding of ATP to the kinase domain of the receptor (24, 25).  
While 50-80% of NSCLC patients harboring mutant EGFR initially respond to gefitinib or 
erlotinib, most patients become resistant to the drug in approximately 6-12 months (26, 
27).  Since treatment with gefitinib or erlotinib is initially effective, it is thought that tumor 
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relapse is the result of acquired resistance.  Although this response can result from diverse 
mechanisms (e.g., MET amplification), more than 50% of NSCLC patients who develop 
resistance to gefitinib or erlotinib develop a second EGFR mutation whereby threonine-
790 is replaced by methionine [T790M, (13, 28-31)].  Development of T790M is thought 
to interfere with drug binding to the EGFR ATP pocket, which leads to resistance to 
gefitinib or erlotinib. 
Diverse approaches have been tested in preclinical and clinical studies in order to 
inhibit EGFR and overcome resistance to TKI treatment in mutant EGFR NSCLC.  
Irreversible EGFR inhibitors such as neratinib and afatinib that bind covalently to EGFR 
have been developed as second generation TKIs; however, preclinical and clinical studies 
have shown that their effectiveness as single interventions is limited (32-34).  Another 
strategy to overcome drug-resistance to TKIs in mutant EGFR NSCLC is targeting heat 
shock protein 90 (HSP90).  Since it has been observed that association of mutant EGFR 
with HSP90 stabilizes the receptor, drugs such as geldanamycin have been used to disrupt 
the interaction between mutant EGFR and HSP90, which results in degradation of the 
receptor and stimulation of apoptosis of mutant EGFR NSCLC cell lines (35).  Despite its 
preclinical effects, it is not known whether HSP90 inhibition is effective in humans with 
mutant EGFR NSCLC.  In addition, studies using L858R+T790M mutant EGFR transgenic 
mice have tested whether combinations of two different types of EGFR inhibitors can 
effectively overcome drug-resistance.  The combination of cetuximab and afatinib resulted 
in decreased tumor growth in this mouse model and in xenograft studies (33).  These results 
indicate that combinations of TKIs with other inhibitors that disrupt additional signaling 
pathways involved in tumorigenesis can be a potentially effective strategy to overcome 
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drug resistance.  In this dissertation, I will discuss my efforts to identify critical oncogenic 
signaling pathways that can be targeted to treat NSCLC patients whose tumors are 
characterized by deregulated signaling via EGFR. 
  
Cyclooxygenase-2 
A signaling pathway that may play important roles in mutant EGFR NSCLC is the 
cyclooxygenase-2 (COX-2) pathway which has been shown to participate in key events in 
tumorigenesis.  COX-2 is an enzyme that contributes to inflammation owing to its role in 
the biosynthesis of prostaglandin precursors.  Specifically, arachidonic acid generated from 
plasma membrane phospholipids is metabolized by COX-2 to prostaglandin endoperoxide 
H2 (PGH2).  PGH2 is then converted to diverse prostaglandin products by downstream 
enzymes such as prostaglandin E synthase (PGES), prostaglandin D synthase (PGDS) and 
prostaglandin F synthase (PGFS).  COX-1 is constitutively expressed in a wide range of 
tissues in mammals.  In contrast, COX-2 expression is induced in settings of inflammation, 
leading to prostaglandin biosynthesis and secretion.  This series of events are required for 
responses such as fever and pain that are typical of physiological inflammation (36, 37). 
Aside from its function in physiological inflammation, COX-2 appears to play a 
critical role in tumorigenesis.  COX-2 overexpression has been reported in various types 
of solid tumors such as colon cancer, esophageal carcinoma, melanoma, pancreatic cancer 
and lung cancer (38-42).  The contribution of COX-2 to tumorigenesis is further supported 
by the observation that COX-2 is a target of oncogenes, tumor suppressors and growth 
factors.  COX-2 expression is regulated by the Wnt and Ras pathways (48).  In addition, 
basic fibroblast growth factor (bFGF) stimulates COX-2 production (49), and COX-2 
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expression is frequently associated with p53 accumulation in ovarian adenocarcinomas 
(49).  Recently, a large number of studies showed that COX-2 contributes to tumor 
initiation, promotion and metastasis of a diverse set of solid tumors (37, 43-47).  Mouse 
models of colon cancer and breast cancer have shown that COX-2 overexpression is 
sufficient to initiate tumor formation (38, 51).  In a transgenic skin tumor mouse model, 
overexpression of COX-2 was not sufficient to develop tumors, but led to increased 
susceptibility to carcinogenesis, suggesting a role for this enzyme in cellular sensitization 
to carcinogens (52).  Additionally, in lung and breast cancers, COX-2 is highly upregulated 
in metastatic cells, and inhibiting COX-2 decreases metastatic phenotypes (53, 54).  
Mechanistically, studies by our group reported that activation of EGFR induces COX-2 
expression, prostaglandin E2 (PGE2) biosynthesis, and release of the EGFR ligand 
transforming growth factor alpha (TGF-α).  These events further activate EGFR, and 
represent a feed-forward autocrine loop that contributes to colon tumorigenesis (55).  These 
observations formed the basis for studies in which I investigated whether deregulated 
COX-2 signaling is also a feature of mutant EGFR lung cancers.  My studies showed that 
these malignancies are characterized by up-regulation of COX-2 expression and signaling, 
and led me to test the hypothesis that targeting COX-2 can have therapeutic utility for the 
treatment of mutant EGFR lung cancer. 
 
Strategies that target EGFR and COX-2 in tumorigenesis 
To inhibit COX-2, I have used celecoxib, the first COX-2 specific inhibitor 
originally used to reduce pain in osteoarthritis, rheumatoid arthritis, painful menstruation 
and ankylosing spondylitis.  Celecoxib effectively relieves pain without the severe side 
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effects associated with the use of conventional nonsteroidal antiinflammatory drugs 
[NSAIDs, (56)].  Despite this advantage, there are potential risks associated with long-term 
celecoxib use, including increased cardiovascular risk and gastrointenstinal bleeding.  
Nonetheless, celecoxib is an attractive therapeutic approach to treat or prevent lung 
tumorigenesis due to its oral bioavailability, widespread use, relatively few side effects, 
and affordability compared to other cancer chemotherapy drugs.  In fact, a large number of 
studies currently are evaluating whether celecoxib prevents tumor development in the lung, 
colon, breast, esophagus, pancreas, liver and brain (57). 
A second approach commonly used to treat tumors is to target distinct oncogenic 
pathways through combination therapies.  For example, combined administration of 
celecoxib and chemotherapeutic drugs such as paclitaxel and carboplatin enhances drug 
responses in patients with early stage NSCLC (58).  Since combined drug strategies appear 
to be more effective than monotherapies in mutant EGFR lung cancer (33, 35), it seems 
logical to target additional components in the central oncogenic pathway in mutant EGFR 
NSCLC.  As noted, COX-2 is likely to participate in tumorigenesis promoted by mutant 
EGFR.  Therefore, in addition to testing the effect of single COX-2 inhibition, I assessed 
the impact of combined COX-2 and EGFR inhibition in the treatment of mutant EGFR 
NSCLC.  Specifically, I tested whether administration of celecoxib in combination with a 
TKI is a reasonable approach to treat mutant EGFR NSCLC. 
 
Protein kinase Cδ: another potential target 
To evaluate additional contributors to the tumorigenic process that is typical of 
mutant EGFR NSCLC, I studied the role of protein kinase Cδ (PKCδ).  The PKC family is 
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a group of serine/threonine kinases involved in the regulation of cell proliferation, survival, 
migration, and apoptosis.  PKC isozymes are subcategorized in three groups based on the 
mechanism of activation: classical PKCs (PKCα, β, γ), novel PKCs (PKCδ, ε, η, θ), and 
atypical PKCs (PKCζ, ι).  PKCs mature through a series of phosphorylation events, and 
mature, “primed,” PKCs are translocated to the plasma membrane and activated by 
increased intracellular calcium and diacylglycerol (59-61).  Importantly, I found that PKCδ 
is primed in mutant EGFR NSCLC, and this observation led me to investigate whether 
PKCδ contributes to the pathogenesis of mutant EGFR NSCLC. 
PKCδ is generally recognized as a tumor suppressor.  This is based on the 
observation that a constitutively-active catalytic fragment of PKCδ cleaved by caspase-3 
migrates to the nucleus and contributes to apoptosis by phosphorylating DNA-dependent 
protein kinase (DNAPK), phospholipid scramblase 1 (PLS1) and lamin B (61-65).  
However, studies in K-Ras lung adenocarcinomas, pancreatic tumors, and ErbB2-driven 
breast cancers, reported that PKCδ can promote tumorigenesis in certain molecular 
contexts (66-68).  These observations combined with our finding that primed PKCδ is a 
feature of mutant EGFR NSCLC led me to conduct studies aimed at characterizing 
potential tumor-promoting roles for PKCδ in mutant EGFR NSCLC, and evaluating 
whether targeting PKCδ could be an effective strategy to treat mutant EGFR NSCLC. 
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 Targeted therapies reduce the growth of mutant epidermal growth factor receptor 
(EGFR) non-small cell lung cancers (NSCLC), but unfortunately most patients develop 
drug-resistance.  This has led to efforts aimed at developing therapies that target resistant 
tumors.  We investigated the role of cyclooxygenase-2 (COX-2) in mutant EGFR NSCLC 
using transgenic mice and human lung cancer cells harboring mutant EGFR and found 
abundant activation of the COX-2 signaling axis.  Targeting COX-2 in human lung cancer 
cells reduced cell proliferation and anchorage-independent growth, and inhibiting COX-2 
in mice harboring mutant EGFR significantly reduced lung tumor growth.  Dual-targeting 
of COX-2 and EGFR had more pronounced effects.  We found evidence that by generating 
prostaglandin E2 (PGE2), COX-2 promotes IL-6 transcription leading to activation of 
STAT3 in an EGFR-independent manner.  Collectively, our studies demonstrate that COX-
2 modulates oncogenic signaling in mutant EGFR lung tumors through the IL-6/STAT3 
signaling axis, and that inhibiting COX-2 could be a viable strategy to treat mutant EGFR 
lung cancers when combined with EGFR inhibition. 
 
Introduction 
Lung cancer causes over 1 million deaths every year worldwide (1) and has been 
the leading cause of cancer-related deaths in the United States for decades (2, 3).  NSCLC 
is thought to originate from lung epithelial cells and comprises about 80% of primary lung 
cancers.  Patients with NSCLC treated with cytotoxic chemotherapy have moderate 
increases in survival, but that comes with significant toxicity (4).  More promising 
strategies that target specific oncogenic mutations essential for tumorigenesis are being 
17 
 
developed.  These therapies can result in cancer cell death with limited side effects.  An 
example of this strategy is the use of specific kinase inhibitors to target tumors harboring 
activated mutant EGFR as a first line therapy.  However, initial positive responses typically 
are followed by development of resistance to EGFR inhibitors (5).  The most common 
cause of resistance is an acquired mutation involving a substitution of threonine to 
methionine at amino acid 790 (T790M) in EGFR (6-9).   
 EGFR resistance has been studied and tested in preclinical and clinical studies.  
First, second generation irreversible EGFR inhibitors have been developed (10-12), but 
despite promising preclinical data, inhibitors such as afatinib are only minimally effective 
in the context of T790M (13, 14).  A second approach to overcome T790M-mediated and 
other forms of resistance is the use of EGFR inhibitors in combination with other inhibitors 
such as cetuximab (11), rapamycin (15), or 17-DMAG (16).  In preclinical studies, these 
strategies led to significantly improved responses, demonstrating that T790M-mediated 
resistance can be overcome by a dual inhibitor approach.  In addition, third generation 
EGFR inhibitors, such as AZD9291 and rociletinib, that specifically target T790M EGFR 
have been developed.  These inhibitors had impressive results in clinical trials, but 
approximately 40-50% of patients failed to respond to them (14, 17).  To identify additional 
options to treat mutant EGFR lung cancer, we sought to find other targetable signaling 
pathways that are important for mutant EGFR tumorigenesis and discovered that COX-2 
acts in concert with mutant EGFR. 
COX-2 is an inflammatory enzyme and its over expression has been reported in 
various types of solid tumors (18-20).  COX-2 is not simply a marker of tumorigenesis as 
numerous studies have shown that it actively contributes to tumor initiation, promotion and 
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metastasis (21).  Studies in cellular and mouse models have shown that COX-2 over 
expression contributes to malignant phenotypes as shown by deregulated cell growth, 
resistance to apoptosis, increased angiogenesis, metastasis, inflammation, and evasion of 
host immune surveillance (18, 22-26).  In this study, we evaluated the role of COX-2 in 
the context of mutant EGFR NSCLC and found evidence that combined inhibition of 
EGFR and COX-2 is a promising strategy to treat mutant EGFR NSCLC. 
 
Results 
The COX-2 / PGE2 axis is activated in mutant EGFR lung tumors 
 Because COX-2 is abundantly expressed in many types of solid tumors and 
participates in tumorigenesis (18-26), we evaluated the COX-2/PGE2 axis in a mouse 
model of mutant EGFR lung cancer using CCSP-rtTA; TetO-EGFRL858R+T790M (EGFR L/T ) 
mice.  These mice harbor a doxycycline-inducible EGFR L/T transgene that promotes lung 
tumorigenesis when the mice receive doxycycline (11).  Control mice had the EGFR L/T 
transgene, but lacked the rtTA transgene necessary to induce EGFR L/T transcription.  As 
expected, we found high levels of EGFR, abundant tyrosine phosphorylated EGFR 
(pEGFR), and strong induction of proliferating cell nuclear antigen (PCNA) in lung tissues 
of EGFR L/T mice, but not control mice (Fig. 2.1A-B).  Lung lysates from EGFRL/T mice 
also demonstrated significantly increased levels of COX-2 and microsomal prostaglandin 
E synthase-1 (mPGES-1), an enzyme that couples with COX-2 to generate PGE2 (Fig. 
2.1B).  Next, we evaluated activity of the COX-2/mPGES-1 synthesis pathway by 
measuring PGE2 metabolites in lung lavage from the mice and found significantly 
increased levels of PGE2 metabolites in EGFR 
L/T mice compared to control mice (Fig. 
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2.1C).  This striking increase in PGE2 is likely due not only to the high levels of COX-2 
and mPGES-1, but also to reduced levels of 15-hydroxy prostaglandin dehydrogenase (15-
PGDH), an enzyme that degrades PGE2, (Supplementary Fig. 2.S1).  Linkage between 
reduced expression of 15-PGDH and tumor progression has been reported in several 
cancers (28-30).  In addition to the mouse model, we evaluated human lung cancer tissues 
harboring mutant EGFR and found high expression levels of COX-2 (Fig. 2.1D). 
Collectively, these data indicate that the COX-2 / PGE2 axis is abundantly active in mutant 
EGFR lung tumors. 
 
COX-2 inhibitors reduce proliferation and anchorage-independent 
growth of human mutant EGFR lung cancer cells 
 To evaluate the contribution of COX-2 to mutant EGFR lung tumorigenesis, we 
tested the effects of inhibiting COX-2 on in vitro tumor cell growth.  We used the human 
mutant EGFR lung cancer cell lines H1975 or H1650 and treated them with celecoxib, a 
specific inhibitor of COX-2, either alone or in combination with afatinib, a second 
generation EGFR inhibitor.  We found that celecoxib reduced cell proliferation by 50% 
when used alone, while combined inhibition with celecoxib and afatinib reduced 
proliferation by more than 80% (Fig. 2.2A).  In anchorage-independent growth assays, we 
found that celecoxib reduced colony growth and that dual-treatment with celecoxib and 
afatinib generally had an even more pronounced effect on colony growth (Fig. 2.2B).  
These data support our hypothesis that COX-2 plays an important role in mutant EGFR 
lung cancer and suggest that targeting COX-2 either alone or in combination with EGFR 







Figure 2.1. The COX-2/PGE2 axis is activated in mutant EGFR lung tumors.  A. H&E and IHC 
staining for EGFR, PCNA, and COX-2 of control or EGFRL/T mouse lung tissues.  Scale bar = 
100μm.  B. Western blots of pEGFR(Y1148), EGFR, COX-2, and mPGES-1 of control or EGFRL/T 
mouse lung lysates.  C. Relative levels of PGE2 metabolites in mouse lung lavage fluid.  EGFRL/T 
mice had 12.1-fold higher levels of PGE2 metabolites than control mice.  Data are presented as 
mean ± SEM.  n = 11 and 16 for control and EGFRL/T, respectively.  p = 0.000003.  D. IHC staining 










Figure 2.2. COX-2 inhibition reduces proliferation and anchorage-independent growth of 
human mutant EGFR lung cancer cells.  A. Cell proliferation under celecoxib, afatinib, or both 
inhibitors.  n = 3 individual experiments.  p-values compared to control (H1975 - ≤ 0.004; H1650 - 
≤ 0.0005).  B. Colony volumes in soft agar under celecoxib, afatinib, or both inhibitors.  n = 30 
colonies (10 from 3 individual experiments).  p-values compared to control (H1975 - ≤ 0.0005; 
H1650 - ≤ 0.01).  NS represents not significant.  All data are presented as mean ± SEM.  
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Dual-targeting of COX-2 and EGFR results in reduced 
tumor growth in mutant EGFR mice 
 To evaluate the effectiveness of combined COX-2 and EGFR inhibition in vivo, we 
used EGFR L/T mice.  Control mice lacking the rtTA transgene necessary to induce EGFR 
L/T transcription or experimental EGFR L/T  mice that harbored both transgenes were treated 
with doxycycline for 5 to 8 weeks followed by CT scanning to quantify tumor loads.  Once 
tumor loads reached about 20% of lung tissue volume (average tumor loads were about 
23%), mice were treated with celecoxib, afatinib, or both medications.  After two and four 
weeks of treatment, all mice were subjected to CT scans to evaluate tumor load (Fig. 2.3A), 
and then after the fourth week scan, mice were sacrificied to collect tissue and lung lavage 
samples.  Using the CT scans, we reconstructed three-dimensional images of the lungs and 
found that tumors in control mice grew rapidly during the four-week period.  Single drug 
treatment with celecoxib or afatinib moderately reduced tumor growth compared to control 
mice, while combined treatment with celecoxib and afatinib more strikingly reduced tumor 
growth (Fig. 2.3B).  Consistent with these changes, we found reduced PCNA levels in mice 
treated with both celecoxib and afatinib (Fig. 2.3C). 
 After quantifying the images at the beginning of treatment and after two and four 
weeks of treatment we found that untreated mice had an average 3.9-fold increase in tumor 
load during the four-week study (Fig. 2.4A and E).  Single drug treatment with either 
celecoxib or afatinib slowed tumor growth, but tumor loads still increased in these mice by 
about 2.6-fold and 1.9-fold, respectively (Fig. 2.4B, C and E).  In contrast to the tumor 
growth that occurred while the mice received single drug treatment, dual drug treatment 





Figure 2.3. Dual-targeting COX-2 and EGFR reduces tumor growth in mutant EGFR mice.  A. 
Timeline for tumor-induction in transgenic mice followed by drug treatment.  Arrowheads indicate 
the time of CT scans.  B. Reconstructed 3-D images of mouse lung tissues from different drug-
treatment conditions.  Reconstructed normal lungs are shown, and tumor tissue is shown as 




study (Fig. 2.4D and E).  This result indicates that dual-targeting of COX-2 and EGFR 
could be an effective strategy to overcome EGFR inhibitor resistance in mutant EGFR lung 
cancer.  Given the abundant activity of the COX-2 / PGE2 axis and the reduced tumor 
growth under COX-2 inhibition, we next sought to identify mechanisms by which COX-2 
contributes to mutant EGFR tumorigenesis. 
 
The COX-2 / PGE2 axis regulates IL-6/STAT3 signaling 
 To identify tumorigenic roles of COX-2 in mutant EGFR NSCLC, we first 
examined canonical EGFR downstream signaling pathways and found that the STAT3 
signaling pathway was consistently activated in lungs from EGFR L/T mice (Fig. 2.5A). 
This is consistent with published studies showing elevated levels of activated STAT3 in 
human tumors harboring mutant EGFR (31).  In that context, STAT3 is activated through 
the IL-6/JAK signaling axis (30), so we  next evaluated IL-6 levels in lavage from EGFRL/T 
mice and found significantly increased levels of IL-6 in EGFR L/T mice compared to control 
mice (Fig. 2.5B).  We also found abundant secretion of IL-6 from mutant EGFR lung 
cancer cell lines (not shown), which was consistent with published data (31), and loss of 
STAT3 phosphorylation in EGFR mutant cells exposed to a JAK inhibitor (Supplementary 
Fig. 2.S2).  Collectively these data indicate that the IL-6/STAT3 axis is highly active in 
EGFR L/T mice. 
 Next, we sought to determine if there is a mechanistic connection between COX-2 
and IL-6/STAT3 signaling by treating H1975 human lung cancer cells with exogenous 
dimethyl-PGE2 to stably mimic COX-2 signaling.  We found that dimethyl-PGE2 increased 





Figure 2.4. Reduced tumor burden in EGFRL/T mouse lungs after 4-week treatment with 
celecoxib and/or afatinib.  Changes in tumor growth in: A. Untreated mice.  p-values compared 
to 0-week treatment are ≤ 0.00001.  n = 11 and 9 at 2 weeks and 4 weeks, respectively; B. 
Celecoxib-treated mice.  p-values compared to 0 week treatment are ≤ 0.004.  n= 10 and 9 at 2 
weeks and 4 weeks, respectively.  C. Afatinib-treated mice.  p-values compared to 0 week 
treatment are ≤ 0.003.  n = 11 and 8 at 2 weeks and 4 weeks, respectively; D. Combined treatment 
with celecoxib and afatinib.  p = 0.0002 and 0.066 for 2 weeks and 4 weeks, respectively.  n = 10.  
A-D. Data are presented as dots indicating fold changes in tumor burden of individual mice, and 
bars indicating mean of each set of mice.  E. Tumor burdens in EGFRL/T mice are compared at the 
4 weeks drug-treatment point.  Data are presented as mean ± SEM.  
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experiment, we tested the effects of inhibiting COX-2 and found that celecoxib reduced 
both STAT3 phosphorylation and IL-6 secretion (Fig. 2.5E and F).  These data suggest that 
the COX-2/PGE2 axis activates STAT3 and IL-6 signaling. 
 
Simultaneous inhibition of COX-2 and EGFR reduces IL-6/STAT3 
signaling in mutant EGFR lung cancer 
 Given our evidence that inhibiting COX-2 reduces signaling through the IL-6 / 
STAT3 axis, we investigated the effects of dual inhibition of COX-2 and EGFR on IL-6 
and STAT3 regulation in tissues from mutant EGFR mice and in human lung cancer cells. 
In mouse lung tissues, we found that both celecoxib and afatinib when used alone 
moderately reduced levels of phosphorylated STAT3 compared to control mice, while 
combined treatment with both inhibitors markedly reduced STAT3 phosphorylation (Fig. 
2.6A).  The increased levels of total EGFR, COX-2 and mPGES-1 in dual-treated mouse 
lung tissues indicate that reduced STAT3 activation occurred in tumor tissue.  Similarly, 
single drug treatment with either celecoxib or afatinib reduced levels of IL-6 in mouse lung 
lavage fluid while combined treatment with both inhibitors significantly reduced IL-6 
levels (Fig. 2.6B).  And consistent with transgenic mice, we found in cultured cells that 
combined inhibition of COX-2 and EGFR reduced phosphorylation of STAT3 and 
secretion of IL-6 compared to single drug treatment (Fig. 2.6C-D).  These results indicate 
that dual-targeting of COX-2 and EGFR can markedly downregulate IL-6/STAT3 
signaling, suggesting that blocking this signaling axis contributed to the reduced lung 
tumor growth that we observed in EGFR L/T mice (Fig. 2.4) since this signaling axis has 







Figure 2.5. The COX-2/PGE2 axis regulates IL-6/STAT3 signaling.  A. Western blots of STAT3, 
AKT, and ERK in mouse lung lysates.  B. Relative IL-6 levels in mouse lung lavage fluids.  n = 10. 
p = 0.0005.  C. Western blots of H1975 cells under 8-Hr diMePGE2 treatment.  D. Relative IL-6 
levels in H1975 culture media under 8 hours treatment with diMePGE2.  n = 3 individual 
experiments.  p = 0.015.  E. Western blots of H1975 cells under 8 hours celecoxib treatment.  F. 
Relative IL-6 levels in H1975 culture media under 8 hours treatment with celecoxib.  n = 3 individual 











Figure 2.6. Dual-targeting COX-2 and EGFR reduces IL-6/STAT3 signaling in mutant EGFR 
lung tumors.  A. Western blots of EGFR, STAT, and COX-2 in mouse lung lysates.  B. Relative 
IL-6 levels in mouse lung lavage fluid.  n = 7, 10, 9, 9, and 10 for control, untreated, celecoxib, 
afatinib, and dually-treated mice, respectively.  p-values compared to control mice are ≤ 0.05. * = 
0.0002, ** = 0.006, *** = 0.004.  C. Western blots of H1975 cells under different drug-treatment 
conditions.  D. Relative IL-6 levels in culture media.  n = 3 individual experiments.  p-values 
compared to control cells are ≤ 0.005.  NS represents not significant.  Data in panels B and D are 




COX-2 regulates IL-6 transcription in an EGFR-independent manner 
 Both COX-2 and EGFR have been shown to promote IL-6 transcription (31-33). 
To evaluate their effects in mutant EGFR lung cancer, we examined IL-6 promoter activity 
in H1975 cells treated with celecoxib, afatinib, or both inhibitors.  Consistent with the 
effects on IL-6 secretion (Fig. 2.6D), we found that combined celecoxib and afatinib 
treatment reduced IL-6 promoter activity by about 55% compared to control cells (Fig. 
2.7A).  We also examined IL-6 mRNA levels under these conditions using real-time RT-
PCR and found similar results (Supplementary Fig. 2.S3A).  
 By promoting PGE2 synthesis, COX-2 has been shown to transactivate EGFR (26), 
suggesting that COX-2 might have been an upstream activator of EGFR in our 
experiments.  To determine if  EGFR is necessary for COX-2 to promote IL-6 transcription, 
we measured IL-6 promoter activity in H1975 cells treated with dimethyl-PGE2 with or 
without afatinib.  We found that while afatinib was responsible for a portion of IL-6 
promoter activity, exogenous dimethyl-PGE2 still increased levels of IL-6 promoter 
activity in the presence of afatinib (Fig. 2.7B).  We also found similar changes in IL-6 
mRNA levels in these conditions (Supplementary Fig. 2.S3B).  Similarly, dimethyl-PGE2 
enhanced STAT3 phosphorylation in the presence of afatinib (Supplementary Fig. 2.S4).  
In contrast, dimethyl-PGE2 did not promote STAT3 phosphorylation in the presence of 
baricitinib, a JAK inhibitor (Supplementary Fig. 2.S4).  Collectively, these data suggest 
that the COX-2/PGE2 signaling axis regulates IL-6/STAT3 signaling independently of 










Figure 2.7. The COX-2/PGE2 axis regulates IL-6 promoter activity in EGFR-independent 
manner.  A. Changes in IL-6 promoter activity compared to DMSO-treated H1975 cells.  n = 3 
individual experiments.  p-values compared to control cells are ≤ 0.0002.  B. Changes in IL-6 
promoter activity compared to DMSO-treated H1975 cells.  n = 3 individual experiments.  Data in 
panels A and B are presented as mean ± SEM.  C. Model of COX-2-regulated IL-6 transcription 





 Driver mutations in tumors such as those that activate EGFR are considered ideal 
targets for cancer therapy, and targeting EGFR has been shown to be superior to 
chemotherapies as first line therapy in lung tumors harboring mutant EGFR (34). 
Unfortunately, most patients who initially respond to EGFR inhibitors eventually develop 
resistance to them by a variety of mechanisms (5).  To overcome this resistance it is has 
become imperative to find additional oncogenic signaling pathways that can be targeted to 
block the resurgent growth. In this study, we found that combined inhibition of COX-2 and 
EGFR reduced tumor loads in EGFR L/T mice and we discovered a novel tumorigenic role 
of COX-2 in the regulation of IL-6/STAT3 signaling in an EGFR-independent manner. 
Our findings suggest that combined inhibition of COX-2 and EGFR could be an effective 
strategy to treat inhibitor resistant, mutant EGFR lung cancer. 
 IL-6 has been implicated as a promoter of lung cancer growth and metastasis (35, 
36), and the IL-6/JAK/STAT3 axis has been shown to be an essential oncogenic signaling 
pathway in human lung adenocarcinomas harboring mutant EGFR (31).  But mechanisms 
of IL-6 expression have not been completely clarified in this context.  Here, we found that 
COX-2/PGE2 signaling promotes IL-6 expression, which leads to enhanced activation of 
the IL-6/STAT3 axis.  Consistent with our findings, PGE2 has been shown to stimulate IL-
6 production and secretion in airway epithelial cells and cancer-associated fibroblasts (32, 
33).  Our observations suggest that IL-6 production is governed by signals emanating from 
both EGFR and the COX-2/PGE2 signaling axis, such that combined inhibition of both 
pathways significantly reduced IL-6 production and secretion, which likely reduced tumor 
growth, cell proliferation, and anchorage-independent growth (Figs. 2.2 and 2.4).  We are 
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currently trying to clarify how COX-2 modulates IL-6 transcription by assessing its role in 
activating known IL-6 transcription factors.  
 Many approaches have been tested in preclinical and clinical studies to overcome 
EGFR inhibitor resistance.  Most of them have focused on intensively targeting EGFR such 
as developing next generation EGFR inhibitors (10, 37), dual-targeting of EGFR (11, 38), 
or inhibiting conformational maturation of EGFR (16).  Although some of these approaches 
have been effective in preclinical studies, their performance in humans has been limited 
(39, 40).  We considered the possibility that focusing solely on EGFR might not be an ideal 
approach to overcome resistance because this strategy would not block parallel oncogenic 
signaling pathways that bypass EGFR.  Our observations suggest that one avenue would 
be to target COX-2, which contributes to mutant EGFR tumorigenesis by promoting 
production of IL-6, leading to STAT3 activation in an EGFR-independent manner.   
 The STAT3 pathway has been studied in the context of mutant EGFR and a 
previous study revealed high levels of phosphorylated STAT3 in mutant EGFR cell lines, 
human lung tumors, and xenografts (31).  In that report, STAT3 was activated by abundant 
IL-6 secreted by lung cancer cell lines in an autocrine/juxtacrine manner, and inhibiting 
IL-6 significantly reduced cell and xenograft growth (31).  Consistent with these findings, 
we found high levels of IL-6 in lung lavage fluid from EGFR L/T mice (Fig. 5B).  The 
oncogenic role of IL-6 in mutant EGFR tumors has been attributed to activation of STAT3 
in the tumor cells, but we also observed in EGFR L/T mice that celecoxib used alone or 
when combined with afatinib significantly reduced the number of CD11b-positive cells 
(presumably macrophages and neutrophils) in mouse lung tissues.  In contrast, afatinib did 
not significantly change the abundance of CD11b-positive cells (not shown).  This 
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observation suggests that COX-2 might promote tumorigenesis not only by activating the 
IL-6/STAT3 axis in the tumor cells, but also by modulating the inflammatory 
microenvironment through IL-6 and/or PGE2.   
 Although we demonstrated that simultaneously targeting COX-2 and EGFR 
significantly reduced lung tumor growth, we did not monitor animal survival and, thus, 
cannot draw conclusions regarding this aspect of our treatment protocol.  Nonetheless, we 
found marked reductions in tumor growth and we did not observe mortality in animals 
treated with both celecoxib and afatinib, while tumors continued to develop and several 
mice had to be sacrificed early in the control and single drug groups.  Collectively, these 
observations lead us anticipate that dual-targeting of COX-2 and EGFR is likely to prolong 
survival in addition to reducing tumor growth.  This outcome might be even more likely if 
celecoxib were combined with newer third generation EGFR inhibitors such as AZD9291 
and rociletinib (14, 17).  We were unable to test this possibility given the pronounced 
responses of EGFRL/T mice to these new inhibitors, which would make it difficult to 
measure additional effects caused by celecoxib. 
 Finally, our findings could carry immediate clinical implications because celecoxib 
is FDA approved, commonly used, and generic.  As such, it could be quickly introduced 
into clinical studies and would be an inexpensive treatment.  We found published clinical 
trials that tested combined COX-2 and EGFR inhibitors in lung cancer (41-45), but none 
of them were selected for EGFR mutation status.  However, within each study, there was 
evidence that subsets of patients who either had EGFR mutations or had clinical profiles 
consistent with EGFR mutations (female nonsmokers) were more likely to respond.  To 
highlight one study testing celecoxib and erlotinib: of seventeen patients in which EGFR 
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mutations were evaluated, five had EGFR mutations and all of them had a partial response. 
In contrast, two of twelve patients with wild-type EGFR had a partial response while the 
others had stable or progressive disease (45).  These findings and our observations suggest 
that combined inhibition of COX-2 and EGFR could be a viable strategy to treat mutant 
EGFR lung cancer. 
 
Materials and methods 
Cell lines and culture 
Human lung cancer cells expressing mutant EGFR, H1650 and H1975, were from 
American Type Culture Collection and grown in RPMI1640 (Invitrogen) with 10% FBS 
and antibiotics. 
 
Cell growth and soft agar assay 
For routine cell growth assays, 20,000 H1650 or H1975 cells were seeded in 
RPMI1640 with 1% FBS and antibiotics in 6cm cell culture dishes (Corning) followed by 
treatment with DMSO, 10μM celecoxib (Cayman Chemicals), 5μM afatinib (LC 
Laboratories), or combination of celecoxib and afatinib.  After 5-6 days of culture, cells 
were harvested, and cell numbers were counted with a hemocytometer.  For soft agar 
growth assays, 1,000 H1650 or H1975 cells were seeded on 0.5% Bacto-Agar (DIFCO) 
RPMI1640 with 10% FBS and antibiotics in 6cm culture dishes followed by treatment with 
DMSO, 10μM celecoxib, 5μM afatinib or combination of celecoxib and afatinib for 2 




Volume = (π/6) X longest diameter X shortest diameter X shortest diameter. 
 
Luciferase assay 
H1975 cells were transfected with the human IL-6 promoter luciferase reporter 
containing a 651-bp sequence upstream of the transcription start site of the human IL6 gene 
(27) followed by treatment for 8 hours with DMSO, 10μM celecoxib, 5μM afatinib, or the 
combination of celecoxib and afatinib.  In some experiments, cells were treated for 30 
minutes with DMSO or 5μM afatinib followed by supplementation with 10μM dimethyl- 
PGE2 (Cayman Chemical) for 8 hours.  The cells were harvested in reporter lysis buffer 
(Promega) and mixed with Luciferase assay substrate (Promega).  Luciferase activities 
were measured by a 2104 EnVision®  Multilabel Plate Reader (PerkinElmer). 
 
Real-time polymerase chain reaction 
Total RNA was extracted using Trizol reagent (Invitrogen).  Quantitative PCR was 
performed using the 7900HT Real-Time PCR system (Applied Biosystems), Power SYBR 
Green PCR master mix (Applied Biosystems), and the following primers:  
Mouse 15-PDGH: 5’- GCCAAGGTAGCATTGGTGGAT-3’ (forward) 
and 5’- CTTCCGAAATGGTCTACAACT-3’ (reverse);  
Human IL-6: 5’-GGTACATCCTCGACGGCATCT-3’ (forward)  
and 5’-GTGCCTCTTTGCTGCTTTCAC-3’ (reverse);  
Human actin: 5’-AGGCACCAGGGCGTGAT-3’ (forward)  
and 5’-TCGTCCCAGTTGGTGACGAT-3’ (reverse).  
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Amplifications were performed under following conditions: 95°C 10min → 95°C 1min (40 
cycles) → 55°C (15-PDGH) / 66°C (IL-6) / 55°C (actin) 30sec → 72°C 45sec → 72°C 
5min (final extension). 
 
Study mice and drug treatment 
All mouse experiments were reviewed and approved by the University of Utah 
Institutional Review Board.  Transgenic mice expressing the reverse tetracycline-
controlled transactivator (rtTA) protein under control of the rat clara cell secretory protein 
(CCSP) gene promoter were obtained from The Jackson Laboratory (stock#006232).  
Mutant EGFR transgenic mice expressing EGFRL858R+T790M with a tetracycline promoter 
were kindly provided by William Pao (Vanderbilt University).  Bi-transgenic CCSP-rtTA; 
TetO-EGFRL858R+T790M or control TetO-EGFRL858R+T790M mice were given doxycycline 
(1mg/L) in the water for 5-8 weeks followed by treatment with celecoxib (University of 
Utah Hospital Pharmacy) mixed into their chow (1mg/g food), afatinib (20μg/g of 
weight/day) by gavage, or combination of celecoxib and afatinib for 4 weeks.  To evaluate 
and quantify tumor development before starting drug treatment, all mice were scanned in 
a small animal Quantum FX microCT (Perkin Elmer) for 4 minutes at 45-μm resolution, 
90kV, with 160-μA current.  Tumor growth in all mice was monitored by CT scans at two 
weeks of treatment and prior to sacrificing them after 4 weeks of treatment. 
 
Histological analysis 
Harvested mouse lungs were fixed in 10% neutral buffered formalin for at least 48 
hours followed by paraffin embedding.  Tissues were sectioned (5μm) and then stained 
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with hematoxylin (Vector Laboratories) and eosin (Sigma Aldrich) according to a standard 
protocol.  Immunostaining was performed using the ABC reagent (Vector Laboratories) and 
anti-EGFR (Epitomics), anti-COX-2 (Santa Cruz Biotechnology), anti-CD11b (Epitomics), 
and anti-PCNA (Epitomics) according to instructions provided by the suppliers. 
 
CT analysis 
All scanned mouse lung images were obtained using Perkin Elmer Quantum FX 
software and analyzed with Analyze 11.0 (AnalyzeDirect) under supervision of two 
pulmonary experts, Matthew Topham M.D. and Aidin Iravani M.D.  To calculate tumor 
volumes from the lung images, the volume of the entire lung tissue was obtained by 
manually outlining lungs every 0.45mm followed by summing up the entire lung volume 
with object propagation for the volume calculation.  Tumor volumes were calculated by 
subtracting the volume of normal lung tissue obtained by extracting normal lung tissue 
based on the contrast threshold from the volume of the entire lung tissue. 
 
Human and mouse IL-6 and PGE2 assays 
Cell culture media were aspirated at the time of harvest and analyzed for IL-6 using 
human or mouse IL-6 ELISA kits (eBioscience).  Mouse lung bronchoalveolar lavage fluid 
samples were collected by dissecting the mice to expose the trachea, injecting cold PBS 
into the trachea, and then withdrawing the fluid.  We then assessed levels of IL-6 and PGE2 






Extracts from H1975 cells and mouse lungs were obtained using a cell lysis buffer 
(Cell Signaling), and aliquots (100μg) then were subjected to immunoblot analyses using 
specific antibodies: pEGFR(Y1148) (Epitomics), EGFR (Epitomics), COX-2 (Santa Cruz 
Biotechnology), mPGES-1 (Agrisera), pSTAT3(Y705) (Cell Signaling), STAT3 (Santa 
Cruz Biotechnology), pAKT(S473) (Cell Signaling), AKT (Cell Signaling), pERK(Y204) 
(Santa Cruz Biotechnology), ERK1 (Santa Cruz Biotechnology), ERK2 (Santa Cruz 
Biotechnology), or β-actin (ICN Biomedicals). 
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Figure 2.S1. Real time PCR relative quantification of 15-PGDH mRNA levels in control or 
EGFRL/T mouse lung tissues.  EGFRL/T mice had lower levels of 15-PDGH mRNA compared to 














Figure 2.S2. JAK inhibition abolishes STAT3 activation in H1650 and H1975 cells.  Western 
blots of STAT3 and pSTAT3(Y705) in H1650 and H1975 cells under 18-hour treatment of JAK 












Figure 2.S3. Real time PCR relative quantification of IL-6 mRNA in H1975 cells. A. Levels of 
IL-6 mRNA were reduced in celecoxib, afatinib, and dual-treated H1975 cells.  Data are presented 
as mean ± SEM.  n = 6 individual experiments.  p-values compared to control cells are ≤ 0.002.  B. 
Levels of IL-6 mRNA in dimethyl-PGE2, afatinib, and dual-treated H1975 cells. Data are presented 













Figure 2.S4. Exogenous dimethyl-PGE2 activates STAT3 in the presence of afatinib, but not 
in the presence of baricitinib.  Western blots of STAT3 and pSTAT3(Y705) in H1975 cells under 







TUMOR PREVENTION BY TARGETING COX-2 
IN EGFRL858R+T790M NSCLC MICE 
 
Abstract 
Up-regulation of COX-2 signaling in mutant EGFR NSCLC activates downstream 
oncogenic pathways such as the IL-6/STAT3 axis.  Due to the importance of these events 
in mutant EGFR NSCLC, I hypothesized that targeting COX-2 with celecoxib is likely to 
be an effective strategy for prevention of this type of NSCLC.  Using two different types 
of mutant EGFR transgenic mouse models in which mice express EGFRL858R or 
EGFRL858R+T790M in the lung, I first investigated whether COX-2 inhibition had an effect 
on tumor formation.  I observed no tumor formation following early treatment of 
EGFRL858R mice with celecoxib.  While this result was consistent with a preventive role for 
celecoxib in lung tumorigenesis, the study did not establish whether the animals in our 
cohorts would have developed tumors had they not been treated with the inhibitor.  In the 
next series of experiments, I utilized computerized tomography (CT) analyses to monitor 
tumor development before celecoxib treatment.  I found that targeting COX-2 prior to 
tumor development caused a slight delay on tumor formation in EGFRL858R+T790M mice 
compared to untreated EGFRL858R+T790M mice.  These results point to the potential utility of 




The inflammatory enzyme COX-2 is not detected in most tissues under basal 
conditions, but its expression is induced by inflammatory stimulation, leading to 
prostaglandin biosynthesis and the promotion of diverse physiological functions including 
fever and pain responses (1, 2).  In addition to roles in inflammation, COX-2 has 
tumorigenic roles.  In a diverse set of in vivo and in vitro studies, overexpression of COX-
2 increased the malignant phenotype of cancer cells including stimulation of cell growth, 
increased resistance to apoptosis, increased angiogenesis and prometastatic effects, robust 
inflammation, and evasion of the host immune surveillance (3-7).  Given its tumorigenic 
roles, COX-2 has been targeted in combination with other anticancer agents or with 
radiotherapeutic approaches to treat cancers of the breast, lung, colon, prostate, pancreas 
and skin with promising preclinical and clinical outcomes (8-13).  In the previous chapter, 
I reported that dual-targeting of EGFR and COX-2 inhibits tumor growth, and that single-
targeting of COX-2 moderately delays tumor progression in EGFRL858R+T790M mice, 
indicating that targeting COX-2 combined with EGFR inhibition is a promising strategy to 
treat mutant EGFR NSCLC. 
In addition to its utility as a component of combination therapies for the treatment 
of advanced tumors, celecoxib has been studied as a chemopreventive agent.  Results from 
several in vivo and in vitro studies suggest that celecoxib prevents tumor formation in 
diverse organs, including colon, skin, oral cavity and bladder (14-17).  Given the potential 
of COX-2 inhibition as a chemo-preventive strategy, I conducted experiments aimed at 





Preventive effect of targeting COX-2 in EGFRL858R mice 
To investigate whether celecoxib has cancer-preventive properties in mutant EGFR 
NSCLC, I treated EGFRL858R mice with celecoxib at very early stages of tumor 
development.  I induced tumor development in 6-week-old transgenic mice expressing 
EGFRL858R in the lung for 4 weeks, as this is normally considered as an initial point of 
tumor development.  This was accomplished by supplementing doxycycline in the drinking 
water.  The initial 4-week period was followed by a second phase during which mice were 
treated with celecoxib (1mg/g of chow) for 4 additional weeks; doxycycline was also 
administered during this phase of the experiment (Fig 3.1 A).  This amount of celecoxib 
leads to clinically relevant serum levels (18).  At the end of the study, I harvested lung 
tissues and assessed the levels of COX-2 and EGFR using immunoblot analysis.  I found 
that tissues from control animals subjected to doxycycline treatment expressed high levels 
of EGFR and COX-2, as expected (Fig. 3.1.B, left panel).  Expression of EGFR and COX-
2 in lung tissues of mice treated with celecoxib was similar to that observed in lung tissues 
from non-transgenic mice (Fig 3.1 B).  In addition, histological analyses revealed that the 
architecture of lung tissues from celecoxib-treated EGFRL858R mice was similar to that of 
nontransgenic normal lung tissues (Fig 3.1 C).  Collectively, these data indicate that 
targeting COX-2 during early stages of tumorigenesis may prevent tumor development. 
Future studies should investigate the dynamics of tumor formation and progression 
before, during and after celecoxib treatment.  Moreover, it will be important to assess 
whether prolonging treatment beyond 4 weeks continues to maintain EGFR and COX-2 








Figure 3.1. COX-2 inhibition is likely to prevent tumor development in EGFRL858R 
mice.  A. Timeline for tumor induction and celecoxib treatment in EGFRL858R mice.  Mice 
(6-week-old) were treated with doxycycline for 4 weeks followed by celecoxib treatment 
for additional 4 weeks.  B. Western blots of EGFR, COX-2, and β-actin in mouse lung 
tissues present reduced levels of EGFR and COX-2 in celecoxib-treated EGFRL858R mice.   
C. H/E staining of mouse lung tissues show the similar lung tissue architectures between 




or no tumor burden. 
 
Verification of tumor development and regression 
in EGFRL858R+T790M mice 
My next goal was to evaluate the reversibility of tumorigenesis in EGFRL858R+T790M 
mice.  I utilized CT scanning methodologies and developed a new timeline of intervention.  
I investigated whether tumor induction and regression could be manipulated by altering the 
content of doxycycline on the drinking water.  Specifically, I treated EGFRL858R+T790M mice 
with doxycycline for 5 weeks to induce tumor development, and confirmed this feature 
using CT scanning (Fig 3.2 A and left panel of B).  To induce tumor regression, I withdrew 
doxycycline for the following 2 weeks and found that the lungs of these EGFRL858R+T790M 
mice appeared normal (Fig 3.2 A and right panel of B).  These data confirmed the 
reversibility of lung tumorigenesis in EGFRL858R+T790M mice.  This finding allowed me to 
next conduct chemopreventive studies in animals that had a demonstrated ability to develop 
lung tumors following induction of mutant EGFR expression. 
 
Moderate preventive effect of targeting COX-2 
in EGFRL858R+T790M mice 
My next goal was to rigorously establish whether celecoxib has chemopreventive 
effects in EGFRL858R+T790M mice.  Since withdrawal of doxycycline restored mouse lungs 
to an apparently normal state, I next treated EGFRL858R+T790M mice with both doxycycline 
and celecoxib for 10 weeks to test the tumor-preventive effects of targeting COX-2.  Tumor 








Figure 3.2. Verification of tumor development and regression in EGFRL858R+T790M 
mice.  A. Timeline for tumor induction and regression in EGFRL858R+T790M mice.  Mice (6-
week-old) were treated with doxycycline for 5 weeks followed by withdrawal of 
doxycycline for the following 2 weeks.   Arrowheads indicate the time of CT scan.  B. CT 
images (upper panel) and reconstructed 3-D images (lower panel) of tumor-induced (left 
panel) and tumor-regressed (right panel).  
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In three-dimensional lung images reconstructed from CT scans, I found that an untreated 
mouse (F3 "19) developed tumors that, by the end of the 10-week treatment, accounted for 
46% of the lung (Fig 3.3 B and C).  Treatment with celecoxib delayed tumor formation and 
progression to various extents.  Two animals (F3 "21 and F3 "32) displayed a slower rate 
of tumor progression compared with the untreated mouse.  By the end of the 10-week 
treatment, tumor loads accounted for only 12% and 25%, respectively (Fig 3.3 C).  The 
effects were less pronounced, but qualitatively similar, in a third animal (F3 "30, Fig 3.3 
C).  These findings point at chemopreventive properties of celecoxib and they suggest that 
COX-2 inhibition prior to tumor development is likely to delay tumor formation and 
progression in NSCLC cases that overexpress mutant forms of EGFR. 
 
Discussion 
Tumorigenic roles of COX-2 and inflammatory signals have been intensively 
studied in colorectal cancer, and the use of COX-2 inhibitors is likely to yield promising 
therapeutic outcomes for the prevention of colorectal cancer by reducing polyp 
multiplicity, tumor incidence, and tumor growth (14, 19-21).  In addition to colorectal 
cancer, targeting COX-2 alone or in combination with other anticancer agents has been 
proposed to prevent tumor formation or recurrence in other types of cancers including those 
of the breast, head and neck, bladder, and lung (22-25).  In the studies reported in this 
chapter, I found that targeting COX-2 with celecoxib is likely to impede tumor formation 
and growth when it is provided prior to tumor development in mutant EGFR mice.  This 
observation has important clinical implications for patients diagnosed with lung tumors 




Figure 3.3. Tumor-preventive effect of COX-2 inhibition in EGFRL858R+T790M mice.  A. 
Timeline for testing tumor-preventive effect of COX-2 inhibition. Mice (6-week-old) were 
treated with doxycycline for 5 weeks followed by withdrawal of doxycycline for the 
following 2 weeks.  After confirming tumor-regression, mice were subjected to celecoxib 
treatment for 10 weeks.  Arrowheads indicate the time of CT scan.  B. Reconstructed 3-D 
images of mouse lungs.  Celecoxib-treated mice (lower 3 panels) present delayed tumor 
development compared to untreated tumor control mouse (top panel).  C. Percentages of 
tumor burden in mouse lung tissues.  Untreated tumor control mouse developed tumor at 
4-week point and show 46% tumor loads at 10-week point.  Celecoxib-treated F3 "30 
mouse developed tumor at 4-week point and show 35% tumor loads at 10-week point.  
Celecoxib-treated F3 "32 and F3 "21 mice developed tumor at 6-week point and show 25% 
and 12% tumor loads, respectively. 
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free drug, using it as a chemopreventive strategy could offer therapeutic benefit for mutant 
EGFR-positive lung cancer patients.  I note that these findings were made in a limited 
number of mice (n for untreated EGFRL858R+T790M: 1, n for celecoxib-treated 
EGFRL858R+T790M: 3).  Thus, it will be necessary to replicate these observations using larger 
mouse cohorts to firmly establish the potential of celecoxib or other COX-2 inhibitors as a 
chemotherapeutic strategy to treat mutant EGFR lung cancer patients. 
 
Materials and methods 
Mice and drug treatments 
All mouse experiments were reviewed and approved by the University of Utah 
Institutional Review Board.  The Jackson Laboratory provided transgenic mice expressing 
the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the rat 
clara cell secretory protein (CCSP) gene promoter (stock#006232).  Mutant EGFR 
transgenic mice expressing EGFRL858R and EGFRL858R+T790M with a tetracycline promoter 
were kindly provided by William Pao (Vanderbilt University).  Bi-transgenic CCSP-rtTA; 
TetO-EGFRL858R or control TetO-EGFRL858R mice received doxycycline (1mg/L) in the 
drinking water for 4 weeks followed by celecoxib treatment (University of Utah hospital 
pharmacy, 200mg/200g) in the food supply for 4 additional weeks.  Mice that had been 
treated for 4 weeks were sacrificed in a CO2 chamber.  Bi-transgenic CCSP-rtTA; TetO-
EGFRL858R+T790M or control TetO-EGFRL858R+T790M mice received doxycycline (1mg/L) in 
the drinking water for 4-5 weeks to induce tumor development.  This was confirmed by 
subjecting the animals to a small animal Quantum FX microCT, (Perkin Elmer) at 45-um 
resolution, 90kV, with 160-uA current.  Induced mice were restored to an apparently 
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normal state by supplying normal water for 2 weeks.  CT scans confirmed that tumors had 
regressed following doxycycline withdrawal.  Inducible normal mice were treated with 
doxycycline and celecoxib for 10 weeks and tumor development and progression was 
monitored uisng by-weekly CT scans.  Following completion of a 10-week treatment mice 
were sacrificed in a CO2 chamber and the lungs were subjected to histological analyses. 
 
Histological analysis 
Harvested lungs were fixed in 10% neutral buffered formalin for more than 48 
hours followed by paraffin embedding.  Sectioned mouse tissues (5μm) were stained with 
hematoxylin (Vector Laboratories) for 10-20 seconds followed by washing with tap water.  
Eosin (Sigma Aldrich) staining was performed for 1 minute followed by washing with tap 
water.  Stained sections were mounted with toluene-based liquid mount media (Triangle 
Biomedical Science).  Stained section images were taken by EVOS FL (University of Utah 
Health Sciences Center core). 
 
Western blots 
Harvested mouse lungs were homogenized using a IKA®  T10 basic ultra-turrax 
homogenizer in cell lysis buffer (Cell Signaling).  Protein concentrations were quantified 
using BCA reagent (Thermo Scientifics), and tissue lysates (100μg of protein) were 
subjected to 10% SDS-PAGE at 35-50 mA for 4-5 hours followed by electroblotting to 
polyscreen PVDF membrane at 500 mA overnight.  To block remaining protein binding 
sites, PVDF membranes were blocked in TBS with 5% milk-TBST for 2 hours.  Separated 
proteins in PVDF membrane were blotted with primary antibodies, EGFR (Epitomics), 
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COX-2 (Santa Cruz Biotechnology), and β-actin (ICN Biomedicals), overnight at 4°C.  
Membranes were washed in TBST for 30 minutes by exchanging fresh TBST three times 
followed by secondary antibody interaction with mouse IgG HRP (Cell Signaling) or rabbit 
IgG HRP antibody (Cell Signaling) at room temperature for 2 hours.  After washing 
membranes in TBST for 30 minutes by exchanging fresh TBST three times, Pierce®  ECL 
western blotting substrates (Thermo Scientific) were applied to the membrane for 1 minute.  
Films (Carestream Biomax MR film) were exposed for various time periods and developed 
in Konica SRX-101A developer. 
 
CT analysis 
All scanned mouse lung images were obtained using Perkin Elmer Quantum FX 
software and analyzed with Analyze 11.0 (AnalyzeDirect) under supervision of two 
pulmonary experts, Matthew Topham M.D. and Aidin Iravani M.D.  To calculate the tumor 
volumes (cm3) from the mouse lung images, the volume of the entire lung tissue was 
obtained by manually outlining lungs every 0.45mm followed by summing up the entire 
lung volume with object propagation for the volume calculation.  Tumor volumes were 
calculated by subtracting the volume of normal lung tissue obtained by extracting normal 
lung tissue based on the contrast threshold from the volume of the entire lung tissue. 
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 CHAPTER 4 
 
ROLES OF PKCδ IN MUTANT EGFR LUNG CANCER  
 
Abstract 
PKCδ, a serine/threonine kinase, is known to regulate cell proliferation, survival, 
migration, and apoptosis.  Previous studies established a proapoptotic role of PKCδ leading 
to the suggestion that PKCδ is a tumor suppressor.  However, studies in pancreatic, breast, 
and lung cancers revealed positive correlations between PKCδ and cancer progression, and 
suggested tumor-promoting roles for PKCδ.  Regulatory factors including localization and 
phosphorylation of PKCδ, and the presence of other proapoptotic or antiapoptotic signals 
are thought to define a role of PKCδ as a tumor suppressor or a tumor promoter.  In this 
chapter, I analyzed lung tumors that developed in transgenic mice expressing 
EGFRL858R+T790M and found increased expression and activation of PKCδ, which led me to 
hypothesize that PKCδ acts as a tumor promoter in the context of mutant EGFR NSCLC. 
I conducted studies in human lung cancer cells in which I manipulated PKCδ levels using 
RNAi and overexpression approaches.  I discovered that PKCδ regulates IL-6 expression 
leading to STAT3 activation.  I also found that depletion of PKCδ decreased the growth of 
mutant EGFR human lung cancer cells.  Collectively, these findings provide novel insights 
regarding tumor-promoting roles of PKCδ in mutant EGFR NSCLC and point at PKCδ as 





The PKC family is composed of several serine/threonine kinases that regulate 
signaling events essential for cell proliferation, differentiation and apoptosis (1-4).  PKCs 
were originally identified as kinases regulated by the phospholipid diacylglycerol (DAG) 
and calcium (5).  Early observations showed that PKC isozymes are activated by tumor-
promoting phorbol esters that are analogs of DAG.  These findings suggested that PKCs 
might have tumor-promoting roles, which led to the proposition that at least some PKC 
isoforms could be suitable targets for cancer therapy (1, 6-7).  Depending on the 
mechanism of activation, PKC isozymes are divided into three groups: classical PKCs 
(PKCα, β, γ), novel PKCs (PKCδ, ε, η, θ), and atypical PKCs (PKCζ, ι).  Each PKC 
isozyme has a distinct tissue distribution, subcellular localization, and substrate specificity. 
PKCs mature through a series of phosphorylation events, and mature or “primed” PKCs 
are translocated to the plasma membrane and become activated by intracellular calcium 
and DAG (8-10).  I found that PKCδ is the only member of the PKC family that is primed 
and becomes highly activated in EGFRL858R+T790M tumors.  This finding led me to 
investigate whether PKCδ has tumor-promoting roles in mutant EGFR lung cancer. 
Like other PKC isozymes, PKCδ is involved in the regulation of cell growth, 
differentiation and apoptosis.  Notably, PKCδ is the first PKC isozyme identified as a 
caspase-3 substrate (11).  A constitutively-active catalytic fragment of PKCδ cleaved by 
caspase-3 localizes to the nucleus and plays proapoptotic roles by targeting DNA-
dependent protein kinase, phospholipid scramblase 1, and lamin B (10, 12-15).  These 
initial findings suggested that PKCδ was a tumor suppressor, and a number of subsequent 




decreased transformation of NIH 3T3 cells (16), and suppressed immunoresponsiveness 
(17).  Further, PKCδ transgenic mice were resistant to 12-O-tetradecanoylphorbol-13-
acetate (TPA)-induced tumor promotion (18).  Conversely, there was transcriptional 
repression of PKCδ in human squamous cell carcinoma (19) and loss of nuclear PKCδ in 
endometrial tumors (20).  Collectively, these findings are consistent with a tumor-
suppressing role of PKCδ. 
In stark contrast to the tumor-suppressing roles described above, recent studies in 
K-Ras lung adenocarcinoma, pancreatic cancer, and ErbB2-driven breast cancer reported 
that PKCδ appears to have tumor-promoting roles.  For example, over-expression of PKCδ 
increased the malignant phenotype of pancreatic cancer cells (21).  Moreover, PKCδ is 
essential for mammary gland tumor development in ErbB2-overexpressing transgenic mice 
(22) and increased PKCδ expression has been reported in ErbB2-positive breast cancers. 
Knocking down PKCδ in K-Ras-driven NSCLC cells decreased cellular growth, migration, 
and transformation (23).  Collectively, these findings indicate that PKCδ can act as a tumor-
promoter in certain types of cancers.  These observations, combined with our findings that 
PKCδ is primed and activated in mutant EGFR NSCLC, led me to investigate whether 
PKCδ has tumorigenic roles in this malignancy. 
 
Results 
PKCδ is “primed” and activated in EGFRL858R+T790M 
mouse and human lung cancer 
My initial approach consisted of investigating the state of activation of canonical 




described in Chapter 2 of this dissertation.  First, I found that STAT3 is highly active in 
mutant EGFR NSCLC (Chapter 2, Fig 2.5).  Second, I discovered activation of PLCγ1 in 
EGFRL858R+T790M mice (Fig. 4.1A).  Since PLCγ1 generates diacylglycerol (DAG), an 
activator of PKCs, I next investigated the activation state of PKC isozymes in 
EGFRL858R+T790M mice.  In general, phosphorylation of PKCs in a hydrophobic motif, such 
as phosphorylation at serine 299 in PKCδ, primes PKCs for subsequent phosphorylation in 
catalytic domains in PKCs, leading to activation of PKCs.  I found increased hydrophobic 
motif phosphorylation in PKCδ in lung tumors from EGFRL858R+T790M mice (Fig. 4.1B).  In 
contrast, increased hydrophobic motif phosphorylation was not observed in other DAG-
activated PKCs, including α, β, γ, ε and η (Fig. 4.1B).  This observation indicates that  
PKCδ is selectively primed in EGFRL858R+T790M tumors, and that this may lead to further 
phosphorylation and full activation.  To address this, I assessed the levels of active PKCδ 
by blotting S299-phosphorylated PKCδ and found high levels of activation in lung tumors 
from EGFRL858R+T790M mice (Fig. 4.1C).  Interestingly, I found increased levels of total 
PKCδ protein in EGFRL858R+T790M compared to control mice that did not express mutant 
EGFR (Fig. 4.1B and C).  These findings were confirmed in histological analyses that 
revealed increased PKCδ protein expression and activation in EGFRL858R+T790M compared 
with control mice (Fig. 4.1D and E).  In addition, in human lung cancer tissue arrays used 
to evaluate mutation-specific monoclonal antibodies (24), I found that human mutant 
EGFR lung tumors present high expression levels of PKCδ (Fig. 4.1F).  Collectively, these 
data indicate that PKCδ is upregulated in mutant EGFR lung cancer, which led us to 





Figure 4.1. PKCδ is primed and activated in mutant EGFR lung cancer.  A. Western 
blots of PLCγ1 in mouse lung tissues present increased activity of PLCγ1(Y783) in 
EGFRL858R+T790M mice.  B. Western blots of pPKC(hydrophobic motif, Ser660) and PKCδ 
in mouse lung tissues present increased levels of pPKC(Ser660) in EGFRL858R+T790M mice.  
C. Active pPKCδ(Ser299) is highly expressed in EGFRL858R+T790M mice.  D. IHC staining 
for PKCδ shows high expression of PKCδ in EGFRL858R+T790M mouse.  E. IHC staining for 
pPKCδ(Ser299) shows high levels of active PKCδ in EGFRL858R+T790M mouse.  F. IHC 
staining for PKCδ shows highly expressed PKCδ in mutant EGFR human lung tissues.  




Depletion of PKCδ decreases mutant EGFR 
lung cancer cell growth 
To test if PKCδ is an important oncogenic signal in mutant EGFR lung cancer, I 
examined the effects of PKCδ inhibition on cell growth.  Human lung cancer cells 
harboring mutant EGFR, H1650 and H1975, were cultured under the condition of PKCδ 
depletion by using PKCδ RNAi oligonucleotides.  Under depletion of PKCδ, cell growth 
of both cell lines was substantially reduced (Fig 4.2), indicating that PKCδ not only has an 
important oncogenic role in mutant EGFR lung cancer cell growth, but it might be a 






Figure 4.2. PKCδ RNAi decreases proliferation of H1650 and H1975 cells.  Under 
PKCδ RNAi, H1650 and H1975 cells show 0.4- and 0.5-fold reduced cell proliferation, 
respectively.  Data are presented as mean ± SEM.  n = 3 individual experiments.  p-values 





Depletion of PKCδ reduces STAT3 activation 
via janus kinases (JAKs) 
Since PKCδ is an important oncogenic signal in mutant EGFR lung cancer, I 
investigated the mechanism of oncogenic PKCδ in the context of mutant EGFR lung 
cancer.  First, I determined if there is a functional relationship between PKCδ and the 
critical oncogenic signal in mutant EGFR lung cancer, STAT3.  To test this, I silenced 
PKCδ expression in H1650 and H1975 cells using RNAi, and then assessed the levels of 
STAT3 activation.  I found that PKCδ RNAi virtually abolished STAT3 activation in both 
cell lines (Fig. 4.3A).  I note that STAT3 inactivation following silencing of PKCδ is 
EGFR-independent because the levels of receptor activation remain high under these 
conditions (Fig 4.3A).  It was previously demonstrated that STAT3 activation in mutant 
EGFR lung cancer is mediated by IL-6 via JAK (25).  Thus, I utilized the JAK inhibitor 
baricitinib and confirmed that inhibition of JAK signaling also inhibited STAT3 activation, 
presumably through IL6 in H1650 and H1975 cells (Fig. 4.3B).  Collectively, these data 
point at a potential role for PKCδ in the regulation of oncogenic events upstream of IL-
6/JAK/STAT3 signaling. 
 
PKCδ regulates IL-6 secretion in mutant EGFR lung cancer cells 
My next goal was to directly test whether PKCδ regulates STAT3 signaling through 
IL-6.  To address this issue, I determined whether silencing PKCδ expression affected the 
levels of IL-6 secreted by H1650 and H1975 into the culture media.  I found that decreasing 
PKCδ reduced IL-6 secretion by 50% in both cell lines (Fig 4.4A), indicating that PKCδ 










Figure 4.3. PKCδ RNAi reduces STAT3 activation via JAKs.  A. Western blots of 
EGFR and STAT3 of H1650 and H1975 cells under PKCδ RNAi show that depletion of 
PKCδ reduces STAT3, but not EGFR activation.  B. Western blots of STAT3 in H1650 
and H1975 cells under JAK inhibition with 250nM baricitinib show that JAK inhibition 





resulted in increased IL-6 secretion about 60% and 30% in H1650 and H1975 cells, 
respectively (Fig. 4.4B).  I note that PKCδ overexpression increased pSTAT3 relative to 
total STAT3 levels (Fig. 4.4B), which is consistent with the findings of decreased STAT3 
activation under PKCδ RNAi (Fig. 4.3A).  Collectively, these findings demonstrate that 
PKCδ regulates IL-6 secretion in mutant EGFR lung cancer cells. 
 
Transcriptional regulation of IL-6 by PKCδ 
Next, to elucidate the mechanism of PKCδ-mediated regulation of IL6 in mutant 
EGFR lung cancer, I investigated whether transcriptional regulatory mechanisms were 
involved in this response, using silencing and overexpression approaches.  I found that 
PKCδ RNAi decreased IL-6 mRNA levels by approximately 50% and 70% in H1650 and 
H1975 cells, respectively (Fig. 4.5A).  Conversely, PKCδ overexpression increased IL-6 
mRNA levels by approximately 4-fold and 2-fold in H1650 and H1975 cells, respectively 
(Fig. 4.5B).  A caveat in the overexpression experiments is that sizeable variations in IL-6 
mRNA levels resulted in differences that did not reach statistical significance (p=0.23 and 
0.1 for H1650 and H1975 cells, respectively).  However, PKCδ overexpression may not be 
an optimal experimental approach to assess cellular responses to enhanced PKCδ signaling.  
As previously noted, PKC isozymes must undergo a series of phosphorylation events for 
full activation, and variations in difficult-to-control culture conditions may alter the extent 
of PKCδ phosphorylation –and thus, activation– in separate experiments.  To address this 
issue, we have generated a constitutively-active PKCδ construct (A147E) (26), which is 
expected to more consistently activate PKCδ signaling.  Nonetheless, results from silencing 









Figure 4.4. PKCδ regulates IL-6 secretion in mutant EGFR lung cancer cells.  A. 
Relative IL-6 levels in culture media of H1650 and H1975 cells under PKCδ RNAi are 0.4- 
and 0.5-fold, respectively, lower than control cells.  Data are presented as mean ± SEM.  n 
= 3 individual experiments.  p-values compared to control cells are ≤ 0.002.  B. Relative 
IL-6 levels in culture media of H1650 and H1975 cells under PKCδ overexpression are 
1.6- and 1.3-fold, respectively, higher than control cells.  Data are presented as mean ± 










Figure 4.5. PKCδ regulates IL-6 transcription in mutant EGFR lung cancer cells.  A. 
Levels of IL-6 mRNA in H1650 and H1975 cells under PKCδ RNAi are 0.45- and 0.28-
fold reduced, respectively, compared to control cells.  Data are presented as mean ± SEM. 
n = 4 individual experiments.  p-values compared to control cells ≤ 0.05.  B. Levels of IL-
6 mRNA in H1650 and H1975 cells under PKCδ overexpression are 3.9- and 2.3-fold 
higher, respectively, than control cells.  Data are presented as mean ± SEM.  n = 3 





EGFR modulates the fate of PKCδ 
My next goal was to contribute additional information regarding the role of PKCδ 
in mutant EGFR lung cancer, with a focus on factors that regulate proapoptotic versus 
prooncogenic roles for this PKC isoform.  Since constitutively active mutant EGFR is the 
oncogenic driver in mutant EGFR lung cancer, I focused on the role of EGFR in the 
regulation of PKCδ functions.  In this regard, it was recently reported that mutant EGFR 
limits the expression of BIM, a proapoptotic protein, through transcriptional and 
posttranslational regulation, leading to the suppression of apoptosis (27-30).  In addition, 
BIM has been shown to induce apoptosis through a caspase-3-dependent mechanism in 
human mast cells (31).  These findings led me to hypothesize that the oncogenic properties 
of PKCδ in mutant EGFR lung cancer could be explained on the basis of antiapoptotic 
effects resulting from mutant EGFR-mediated effects on BIM and caspase-3.  To test this 
hypothesis, I assessed the effect of EGFR inhibition on PKCδ expression using the mutant 
EGFR lung cancer cell HCC827.  I found that when EGFR signaling was inhibited with 
afatinib, the levels of constitutively-active catalytic fragments of PKCδ (δCF) were 
significantly increased (Fig 4.6A).  This result is consistent with a model whereby 
inhibiting EGFR changes the function of PKCδ from prooncogenic to proapoptotic in 
mutant EGFR lung cancer cells.  I note that EGFR is not involved in the regulation of PKCδ 
expression since there were no effects of EGFR inhibition on PKCδ protein levels.  
However, it is possible that EGFR may be involved in the generation of active PKCδ 
fragments by activating the proteolytic step, for example.  Aside from the mechanism, the 
findings shown in Fig. 4.6A indirectly support the hypothesis that the antiapoptotic roles 




EGFR lung cancer (Fig 4.6B).  To rigorously establish whether EGFR controls 
prooncogenic versus antioncogenic roles for PKCδ, it will be required to assess detailed 
functional relationships among EGFR, BIM, caspase-3 and PKCδ. 
 
Discussion 
In this study, I discovered a novel prooncogenic function of PKCδ in the regulation 
of IL-6/STAT3 signal in mutant EGFR lung cancer.  The studies suggest that PKCδ 
regulates IL-6 transcription at the transcriptional level.  While over-expression studies were 
variable possibly owing to experimental limitations, this problem can potentially be solved 
using a plasmid construct expressing active pPKCδ (A147E) (26).  This expression 
construct has been generated, and it will be utilized in future studies to further test the 
impact of pPKCδ on transcriptional regulation of IL6 expression in mutant EGFR lung 
cancer cells. 
In this chapter, I also addressed the mechanism that leads to dual—prooncogenic 
and proapoptotic—roles of PKCδ in mutant EGFR lung cancer.  I made the novel 
observation that EGFR inhibition leads to increased levels of δCF and, based on this result, 
I speculate that EGFR may determine whether PKCδ functions as a proapoptotic versus 
prooncogenic factor (Fig 4.6B).  To further define the mechanism by which mutant EGFR 
modulates proapoptotic and prooncogenic functions of PKCδ in mutant EGFR lung cancer, 
our laboratory is aiming to address the following issues: (1) How does EGFR inhibition 
increase production of δCF? (2) How does EGFR signaling activate prooncogenic 
functions of PKCδ? (3) Does mutant EGFR alter the subcellular localization of PKCδ? (4) 











Figure 4.6. EGFR inhibition increases the generation of active PKCδ fragments in 
mutant EGFR lung cancer cells.  A. Western blots of pEGFR(Y1148) and PKCδ show 
that active PKCδ fragments are increased under 1μM afatinib treatment for 18 hours in 
serum-free RPMI1640 culture media.  B. The current model of an apoptotic role of PKCδ 
is shown in the red box.  In the hypothetic model of an antiapoptotic role of EGFR, EGFR 






Finally, reduced cancer cell growth under PKCδ depletion implies that targeting 
PKCδ is a potential therapeutic strategy to treat mutant EGFR lung cancer, which is 
supported by recently published studies showing that inhibition or depletion of PKCδ leads 
to reduced proliferation and enhanced apoptosis in prostate, pancreatic, and cancer stem 
cells (32-34).  In the previous chapter, I proposed, tested, and verified the efficacy of 
targeting both EGFR and COX-2, an additional oncogenic signaling axis, to treat mutant 
EGFR lung cancer.  In addition, I discovered that COX-2 and PKCδ have similar oncogenic 
roles by regulating IL-6/STAT3 signal in the context of mutant EGFR lung cancer.  These 
combined findings point at PKCδ as an additional target that, combined with EGFR 
inhibitors, could be used to treat mutant EGFR lung cancer.  In order to test the impact of 
combined EGFR and PKCδ inhibition, future studies will assess the effect of afatinib or 
third generation EGFR inhibitors such as AZD9291 (35, 36) combined with specific 
peptides or small molecule PKCδ inhibitors (37, 38) on lung tumorigenesis, using mice 
expressing EGFRL858R+T790M. 
 
Materials and methods 
Mice 
All mouse experiments were reviewed and approved by the University of Utah 
Institutional Review Board.  The Jackson Laboratory provided transgenic mice expressing 
the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the rat 
clara cell secretory protein (CCSP) gene promoter (stock#006232).  Mutant EGFR 
transgenic mice expressing EGFRL858R and EGFRL858R+T790M with a tetracycline promoter 




TetO-EGFRL858R+T790M or control TetO-EGFRL858R+T790M mice were given doxycycline 
(1mg/L) in the water for 10 weeks to induce tumor development.  To confirm tumor 
development, doxycycline-induced mice were subjected to a small animal Quantum FX 
microCT, (Perkin Elmer) at 45-um resolution, 90kV, with 160-uA current.  Tumor-
harboring mice were sacrificed in CO2 chamber for further analysis. 
 
Histological analysis 
Harvested mouse lungs were fixed in 10% neutral buffered formalin for more than 
48 hours followed by paraffin embedding.  An array of human lung cancer tissues was 
obtained from Memorial Sloan-Kettering Cancer Center.  Sectioned mouse tissues (5μm) 
and human tissue arrays were immunostained with antibodies against PKCδ (Santa Cruz 
Biotechnology) and pPKCδ(S299 (Epitomics) using ABC reagent (Vector Laboratories) 
and ImmPACTTM DAB (Vector Laboratories) followed by counterstaining with 
hematoxylin (Vector Laboratories).  Stained sections were mounted with toluene-based 
liquid mount media (Triangle Biomedical Science).  Stained section images were taken by 
EVOS FL (University of Utah Health Sciences Center core). 
 
Western blots 
Harvested mouse lungs were homogenized using an IKA®  T10 basic ultra-turrax 
homogenizer in cell lysis buffer (Cell Signaling).  Harvested H1650, H1975 or HCC827 
cells were lysed in cell lysis buffer.  Protein concentrations were quantified using BCA 
reagent (Thermo Scientifics), tissue or cell lysates containing 100μg of total protein were 




to a polyscreen PVDF membrane at 500 mA.  To block remaining protein binding sites, 
PVDF membranes were blocked in TBS with 5% milk-TBST for 2 hours.  Separated 
proteins in PVDF membrane were blotted with primary antibodies, pEGFR(Y1148) (Cell 
Signaling), EGFR (Epitomics), PLCγ1 (Upstate biotechnology), pPLCγ1(Tyr783) (Cell 
Signaling), pPKC(S660) (Cell Signaling), pSTAT3(Y705) (Cell Signaling), STAT3 (Santa 
Cruz Biotechnology), PKC δ (Santa Cruz Biotechnology), pPKCδ(S299) (Epitomics), and 
β-actin (ICN Biomedicals) overnight at 4°C.  Membranes were washed in TBST for 30 
minutes by exchanging fresh TBST three times followed by secondary antibody interaction 
with mouse IgG HRP (Cell Signaling) or rabbit IgG HRP antibody (Cell Signaling) at room 
temperature for 2 hours.  After washing membranes in TBST for 30 minutes by exchanging 
fresh TBST three times, Pierce®  ECL western blotting substrates (Thermo Scientific) were 
applied to the membrane for 1 minute.  Films (Carestream Biomax MR film) were exposed 
for various time periods and developed in Konica SRX-101A developer. 
 
Cell growth assay 
H1650 and H1975 cells (20,000/well) were seeded in RPMI1640 (Life 
Technologies) with 10% FBS (Life Technologies) and 1% Penicillin-Streptomycin (Life 
Technologies).  The cells were subjected to PKCδ or control RNAi, as described below.  
The cells then were exposed to culture media supplemented with 1% FBS and 1% 
Penicillin-Streptomycin and allowed to proliferate for 5 days.  We then harvested and 







Cells were transfected with annealed RNAi oligonucleotides (20μM) using 
Oligofectamine®  (Invitrogen) in Opti-MEM®  (Lift Technologies) for 4-5 hours, and then 
grown in RPMI1640 with 10% FBS for 24-48 hours.  Sequences of PKCδ RNAi 





pMyc-CMV empty vector (Clontech) or p3XMyc-PKCδ plasmids were transfected 
using Lipofectamine®  (Invitrogen) in serum-free RPMI1640 for 5 hours.  The cells were 
then grown in RPMI1640 with 10% FBS for 24-48 hours. 
 
Human IL-6 ELISA 
PKCδ-silenced and PKCδ-over-expressing H1650 and H1975 cells were serum-
starved for 2 hours.  The levels of IL-6 were determined in the culture media using the 
Human IL-6 ELISA Ready-SET-Go Kit (eBioscience), following the instructions provided 
by manufacturer. 
 
Relative quantification of realtime RT-PCR 
Total RNA from PKCδ-silenced and PKCδ-over-expressing H1650 and H1975 
cells was extracted using Trizol reagent (Invitrogen).  Extracted 2μg of RNA were 




transcriptase (Fermentas) at 37°C for 1 hour.  Synthesized cDNAs were mixed with Power 
SYBR Green PCR master mix (Applied Biosystems) and the following primers: 
PKCδ (Forward): 5’-AAAGGCAGCTTCGGGAAGGT-3’ 
PKCδ (Reverse): 5’-TGGATGTGGTACATCAGGTC-3’ 
β-actin (Forward): 5’-AGGCACCAGGGCGTGAT-3’ 
β-actin (Reverse): 5’-TCGTCCCAGTTGGTGACGAT-3’ 
Realtime RT-PCR was performed with the 7900HT Real-Time PCR system 
(Applied Biosystems) at the University of Utah Health Sciences Center core. 
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Targeting EGFR is a promising therapeutic strategy to treat mutant EGFR NSCLC, 
and TKIs such as erlotinib and gefitinib are an effective approach to treat mutant EGFR 
NSCLC (1-4).  However, most patients undergoing therapy with TKIs develop drug 
resistance within 6-12 months (5, 6).  It has been proposed that combined inhibition of 
EGFR and additional oncogenic signaling pathways can potentially be a therapeutic 
strategy to overcome drug resistance in mutant EGFR NSCLC (7-9).  In this dissertation, 
I identified COX-2 and PKCδ as novel additional targets for the treatment of mutant EGFR 
NSCLC and defined mechanisms whereby these enzymes contribute to oncogenesis in 
settings of mutant EGFR NSCLC. 
 
Targetable COX-2 in mutant EGFR NSCLC 
The goal of my studies was to identify key oncogenic pathways and to develop 
targeted strategies that can be utilized in combination with EGFR inhibitors to treat mutant 
EGFR NSCLC.  In addition to its well-recognized functions in inflammation, COX-2 has 
been shown to have tumorigenic roles in various types of solid tumors (10-14).  Previous 
work performed by members of our team identified a critical tumorigenic role for COX-2




COX-2 is upregulated when EGFR is activated in colon cancer led me to conduct studies 
aimed at addressing whether COX-2 is upregulated in mutant EGFR NSCLC.  First, I found 
that COX-2 expression is upregulated in models of mutant EGFR NSCLC.  Second, I 
observed that signaling events regulated by COX-2 control IL-6 expression at the 
transcriptional level in mutant EGFR NSCLC.  These observations suggested that COX-2 
could have oncogenic roles in this disease and identified this enzyme as a novel therapeutic 
target for mutant EGFR NSCLC. 
I directly tested the suitability of inhibiting COX-2, either alone or in combination 
with an EGFR inhibitor, in models of mutant EGFR NSCLC.  I found that dual-targeting 
of COX-2 and EGFR inhibited tumor cell growth in vivo and in vitro.  These findings are 
consistent with previous studies in models of colorectal, breast and lung cancers in which 
COX-2 inhibition was found to have promising anticarcinogenic effects when combined 
with chemotherapeutic or radiotherapeutic approaches (16).  Importantly, my work also 
suggests that a regimen based on single COX-2 inhibition delays tumor formation in 
transgenic mice, pointing to potential chemopreventive uses for COX-2 inhibitors in 
NSCLC.  This is in agreement with multiple studies that have consistently shown reduced 
polyp multiplicity and colorectal cancer incidence following COX-2 inhibition (17-19).  
The anticancer effects of targeting COX-2 on mutant EGFR NSCLC imply that COX-2 
inhibition, when combined with EGFR inhibitor, is likely to be an attractive strategy to 
treat mutant EGFR lung cancer.  Importantly, clinical studies aimed at assessing the 
efficacy of COX-2 inhibition in lung cancer could potentially be implemented in a 
straightforward manner.  COX-2 inhibitors such as celecoxib are low cost, commonly used, 




Role of COX-2 in the tumor-microenvironment 
While conducting animal studies aimed at understanding the role of COX-2 in lung 
tumorigenesis, I made intriguing observations that led me to develop an additional set of 
studies related to the impact of COX-2 on immune responses.  Specifically, I found that 
inhibition of COX-2 eliminated the characteristic infiltration of mouse lung tumors with 
CD11b+ cells (Fig. 5.1).  Other groups also reported that COX-2 inhibition significantly 
decreased accumulation of CD11b+ cells and restored the activity of natural killer cells in 
other tissues including spleen, bone marrow, and skin (20, 21).  CD11b+ cells are major 
producers of chemokines that function to recruit additional inflammatory cells (22).  It was 
recently reported that infiltration of CD11b+ cells is markedly increased in tumor tissues, 
and that these cells establish a microenvironment that supports tumorigenesis by inhibiting 
T cell activation in colorectal and liver cancer (23, 24).  My observations, combined with 
these reports, suggest that signaling events regulated by COX-2 may be involved in 
recruitment of CD11b+ cells to the tumor microenvironment, and that this is likely to favor 
tumor growth.  The findings constitute an additional line of evidence supporting the utility 
of targeting COX-2 in mutant EGFR NSCLC. 
 
PKCδ: Is it oncogenic and targetable in mutant EGFR NSCLC? 
In related work, I investigated other potential strategies that could be used to 
prevent or overcome TKI-resistance in mutant EGFR NSCLC.  I found that PKCδ is 
increased in protein and activity levels in mutant EGFR tumor mice.  Although PKCδ is 
known to play proapoptotic roles in various types of cells, depletion of PKCδ resulted in 










Figure 5.1. Eliminated recruitment of CD11b+ cells in mouse lung tissues under COX-
2 inhibition.  IHC staining for CD11b shows that COX-2 inhibition results in eliminated 
CD11b-staining in EGFRL858R+T790M mouse lung tissues.  Sectioned mouse lung tissues 
(5μm) were immunostained with CD11b antibody (Epitomics) using ABC reagent (Vector 
Laboratories) and ImmPACTTM DAB (Vector Laboratories) followed by counterstaining 





likely involves downregulation of IL-6/STAT3 signaling.  Considering its generally 
accepted roles as a proapoptotic protein, it was surprising that PKCδ had tumor-promoting 
effects in mutant EGFR NSCLC cells.  I hypothesized that EGFR signals might participate 
in the definition of proapoptotic versus proliferative functions of PKCδ.  Interestingly, I 
found that EGFR inhibition, which is known to induce apoptosis, also led to significantly 
increased levels of potentially proapoptotic PKCδ catalytic fragments.  These correlative 
findings are consistent with a model whereby PKCδ promotes lung tumorigenesis by 
limiting apoptotic responses.  This constitutes an additional line of evidence supporting 
inhibition of PKCδ as a strategy to treat mutant EGFR NSCLC. 
 
Open question: Is there a connection between COX-2 and PKCδ? 
In this dissertation, I found that COX-2 and PKCδ are potential targets to treat 
mutant EGFR NSCLC.  Using mechanistic studies, I discovered that both COX-2 and 
PKCδ are involved in the regulation of IL-6 expression and STAT3 activation in mutant 
EGFR NSCLC.  These observations suggest that there may be a functional link(s) between 
COX-2 and PKCδ, and that this may be important in the regulation of IL-6 levels.  
Interestingly, mechanistic studies in glioma and colon carcinoma cells revealed that 
expression of COX-2 is regulated by PKCδ in an EGFR-dependent manner (25, 26), 
suggesting that PKCδ may function upstream of COX-2.  However, I found that COX-2 
regulates IL-6 expression in an EGFR-independent manner.  Thus, the EGFR-PKCδ-COX-
2 axis proposed to function in some tumor models does not appear to operate in mutant 
EGFR NSCLC.  In summary, it is unclear whether the regulation of IL-6 expression is 




COX-2-mediated control of IL-6 levels occurs through EGFR-independent mechanisms.  
Future studies establishing that inhibition and/or silencing of COX-2 affects PKCδ-
mediated regulation of IL-6 expression would provide evidence for a COX-2→PKCδ 
functional link.  Similar approaches can test whether PKCδ functions upstream of COX-2 
to regulate IL-6 levels in mutant EGFR NSCLC. 
 
Oncogenic role of the IL-6/STAT3 axis in mutant EGFR NSCLC 
I found that both COX-2 and PKCδ contribute to regulation of IL-6 at the 
transcriptional level, which leads to further activation of STAT3 via JAK in mutant EGFR 
lung cancer cells.  A large number of studies have demonstrated that IL-6 and STAT3 are 
involved in regulation of diverse cellular signaling pathways including differentiation, 
proliferation, apoptosis, angiogenesis and recruitment of immune cells (27-29).  Consistent 
with my findings, activation of IL-6 and STAT3 has been linked to many types of cancers 
including myeloma, breast cancer, prostate cancer, head and neck cancer, and NSCLC (30-
35).  Even though STAT3 activation occurs transiently in normal cells, it has been 
demonstrated that STAT3 activation is persistent in most malignant cancer cells due to 
increased production of cytokines and cytokine receptors (34, 36).  Persistent activation of 
STAT3 in cancer cells is involved in cancer development, progression and survival by 
regulating expression of genes governing cell cycle, survival and angiogenesis (37-39).  
Since I found persistent activation of STAT3 in mutant EGFR NSCLC, it is reasonable to 
speculate that the IL-6/STAT3 axis contributes to oncogenesis similar to its role in other 
cancers.  As such, elucidating functional roles of IL-6/STAT3 axis in mutant EGFR 




establish strategies to treat this type of cancer.  Indeed, due to its importance in 
tumorigenesis, targeting STAT3 and its upstream IL-6 and JAK has been proposed as a 
potential strategy to treat other types of cancer.  Although most current STAT3 inhibitors 
are not potent enough to advance to clinical levels, monoclonal antibodies against IL-6 or 
its receptor and JAK inhibitors have shown promising outcomes in clinical trials (40).  
Hence, targeting IL-6, IL-6 receptor, or JAK in combination with an EGFR inhibitor could 
be another potential strategy to treat mutant EGFR NSCLC. 
 
Future directions 
My studies showing that COX-2 regulates IL-6 transcription in mutant EGFR 
NSCLC open avenues for future investigations to define the mechanism of this response.  
For example, it would be important to investigate participation of signaling events likely 
to function downstream of COX-2, such as PKA and β-catenin.  The finding that 
recruitment of CD11b+ immune cells to lung tumors is robustly inhibited by inhibition of 
COX-2 suggests additional roles for this enzyme in the regulation of environmental events 
outside of tumor cells.  In addition, studying the impact of CD11b+ cells recruitment to the 
tumor microenvironment is likely to provide additional insight into the role of COX-2 in 
mutant EGFR NSCLC.  A second area for future development is related to studies showing 
that single inhibition of COX-2 delayed tumor formation in transgenic mice.  While I 
recognize that these studies involved a small number of animals, this finding is potentially 
important for development of future chemotherapeutic prevention strategies.  Finally, the 
discovery that PKCδ has tumorigenic effects in mutant EGFR lung cancer cells sets the 




therapeutic utility of targeting PKCδ singly or in combination with TKIs to treat drug-
resistant mutant EGFR NSCLC also should be evaluated. In this regard, it will be essential 
to elucidate the mechanism whereby EGFR signaling controls the switch between 
prooncogenic and proapoptotic effects of PKCδ. 
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